Decoding D-Dimer Levels: What They Mean for Urticaria Treatment Success
"A deeper look into how D-dimer levels correlate with Omalizumab treatment response in chronic spontaneous urticaria patients."
Chronic Spontaneous Urticaria (CSU), characterized by persistent hives and itching, can significantly impact the quality of life. While antihistamines are often the first line of defense, many patients find themselves resistant to these treatments, leading to a search for alternative solutions. Omalizumab (OMA), a monoclonal antibody, has emerged as a promising add-on therapy for those with inadequate response to antihistamines.
A key area of interest in CSU research is identifying biomarkers that can predict treatment response. Among these, D-dimers (D-D), byproducts of fibrin degradation, have shown potential links to the severity of CSU and how well patients respond to treatment. Increased D-D levels often indicate heightened disease activity and poorer response to conventional therapies.
The SUNRISE study, a French prospective noncomparative phase 4 study, explored the correlation between D-D levels and treatment response to Omalizumab in CSU patients. This article delves into the findings of the SUNRISE study, examining how D-dimer levels fluctuate with Omalizumab treatment and whether they can serve as a predictive marker for treatment success. By understanding this relationship, clinicians may be able to better tailor treatment strategies for CSU patients.
D-Dimer as a Treatment-Response Marker
A study titled “Evaluation of D-dimer levels as a marker of chronic ...” reports that D-dimer levels can be used as a screening tool for suspected antihistaminic resistance in chronic urticaria. It also describes using D-dimer to monitor response to therapy with alternative agents. The supplied source does not provide prevalence figures or numerical estimates of impact.
D-Dimer and Disease Severity
In a study of chronic urticaria, patients with severe, spontaneous, and difficult-to-control disease had elevated serum D-dimer levels and a positive autologous serum test. The same source reports little correlation between chronic spontaneous urticaria severity and C-reactive protein levels. These findings describe associations in the studied patients; the supplied source does not establish D-dimer as a standalone measure of severity.
SUNRISE Study: Linking D-Dimer Levels and Omalizumab Response
The SUNRISE study included patients with CSU for at least six months who had shown resistance to antihistamine (AH1) treatment. These patients also had a UCT (Urticaria Control Test) score of less than 8, indicating poorly controlled disease. Participants received 300 mg of Omalizumab subcutaneously at the beginning of the study (Day 0) and then again at weeks 4 and 8. Researchers assessed blood D-D levels using a turbidimetric immunoassay at baseline (D0), week 4 (W4), and week 8 (W8).
- Elevated Baseline D-D Levels: At the start of the study, the median D-D level in the 112 patients was increased (618 ng/mL, range 108-5,170), suggesting heightened disease activity.
- Normalization with Omalizumab: As early as week 4 (W4), D-D levels began to normalize, reaching 286 ng/mL (108-481) by week 8 (W8). This indicates that Omalizumab treatment may help to reduce fibrin degradation.
- Weak Correlation with UAS7 Score: The correlation between D-D concentration and UAS7 score at week 12 (W12) was weakly positive (Spearman coefficient 0.108). This suggests that while there is a relationship between D-D levels and clinical response, it is not strong enough to be the only factor.
- High Baseline D-D and Treatment Response: Among the 10 patients with very high baseline D-D levels (>3,000 ng/mL), 8 were responders (UAS7 ≤6) at W12.
Clinical Assessment Remains Important
A 2025 article on clinical evaluation and outcome measures describes chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU) as debilitating diseases involving recurrent itchy wheals and/or angioedema, with considerable negative effects on quality of life. It emphasizes that accurate clinical evaluation is important for diagnosis, disease monitoring, and guiding treatment. A separate study frames its objective as examining the relationship between plasma D-dimer levels and chronic urticaria severity, while noting that earlier studies found levels paralleled disease severity. Together, these sources underscore the need for clinical evaluation alongside investigation of biomarkers.
Comparisons Across Disease and Treatment Groups
One study reported that patients with chronic urticaria had 18.0 times the odds of elevated D-dimer levels compared with patients with psoriasis. A 2013 study found that, among patients with similar disease severity, those with elevated D-dimer were more often cetirizine-resistant, particularly at moderate urticaria severity (UAS 3 and 4; P < .001 for both). Another source describes CSU as the most common form of chronic urticaria and gives its prevalence as 0.5% to 5%. These findings concern different comparisons and do not by themselves establish that D-dimer predicts treatment outcomes for every patient.
Future Directions: Unlocking the Predictive Power of D-Dimers
The SUNRISE study has opened avenues for further research. While it demonstrated a weak correlation between D-D levels and Omalizumab response, it also highlighted the potential of D-D levels as a biomarker. By exploring the impact of Omalizumab on DD levels, the study encourages a more in-depth evaluation of its predictive value for treatment response.
Evidence on D-Dimer and Urticaria Activity
A study comparing chronic refractory urticaria (group 1) with another chronic urticaria group (group 2) reports significantly higher D-dimer levels in group 1. Its methods included an unpaired t-test for comparing two groups and Pearson’s correlation coefficient to assess the relationship between D-dimer and the 7-day Urticaria Activity Score (UAS-7). A separate study evaluated plasma D-dimer correlation with chronic urticaria activity in 40 patients at the dermatology outpatient clinic of Al Azhar University Hospital in Damietta, Egypt. The supplied summaries do not give a numerical correlation result that would establish the strength of that relationship.
D-Dimer in Broader Disease Context
A study of chronic urticaria describes the condition as having a significant impact on quality of life and investigates D-dimer in relation to disease severity and treatment response. A 2026 source discusses chronic urticaria, psoriasis, and urticarial vasculitis as inflammatory skin diseases with frequent systemic implications, and describes serum D-dimer as a coagulation-activation marker suggested for evaluating systemic inflammation in autoimmune diseases. A 2022 overview focuses on studies of plasma D-dimer as a biomarker for disease activity and treatment response in chronic urticaria. These sources present D-dimer as an area of investigation rather than providing a shared, definitive clinical conclusion.
Future studies with larger cohorts and more detailed subgroup analyses are needed to fully understand the relationship between D-D levels and clinical outcomes. These analyses may reveal specific patient profiles for whom D-D levels are a more reliable predictor of treatment success.
Ultimately, incorporating D-dimer level monitoring into clinical practice could help personalize treatment strategies, ensuring that patients receive the most effective therapy for their specific condition. This will not only improve patient outcomes but also optimize healthcare resource utilization.